The best candidates for discontinuation of nucleos
Loss of HBsAg in patients with chronic hepatitis B (CHB) is rare during treatment with nucleos
Among the 1552 CHB patients included, the cumulative probability of HBsAg loss was 3.2% at 12 months and 13.0% at 48 months of follow-up. HBsAg loss was more common in Caucasian patients (vs. Asians: sub-distribution HR (SHR) 6.8; 95% CI 2.7-16.8; p < 0.001) and in patients with HBsAg levels < 100 IU/ ml at the end of treatment (vs. ≥ 100 IU/mL: SHR 22.5; 95% CI 13.1-38.7; p < 0.001). At 48 months of follow-up, Caucasian patients with HBsAg levels < 1000 IU/ml and Asian patients with HBsAg levels 30%). The incidence of hepatic decompensation and hepatocellular carcinoma was 0.48 per 1000 person-years and 0.29 per 1000 person-years, respectively. 7 of the 19 decompensated patients and 2 of the 14 patients with hepatocellular carcinoma died.
You may also be interested in: Immunogenicity and Safety of a Tri- vs. Mono-antigenic Hepatitis B Vaccine
Bron:
Hirode G, Choi HS, Chen CH, et al. Off-Therapy Response After Nucleos
–
